Cytokine Patterns in Brain Tumour Progression

Albulescu, Radu; Codrici, Elena; Popescu, Ionela Daniela; Mihai, Simona; Necula, Laura; Petrescu, Daniel; Teodoru, Mihaela; Tănase, Cristiana

doi:10.1155/2013/979748

Cited by 137 publications

(113 citation statements)

References 46 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Similarly, our results indicated that the IL-4 and IL-8 levels in serum were highly increased in patients with large cell lung carcinoma compared to non-cancer controls and to patients with adenocarcinoma as well as squamous cell lung carcinoma. Taken together, IL-1β, IL-4, IL-6 and IL-8 levels have been found to be elevated in most patients suffering from different common cancers [49,50]. Our results indicate that large cell lung carcinoma is associated with a systemic alteration in cytokines (IL-1β, IL-4, IL-6 and IL-8) and these cytokines have been shown to promote tumour growth and metastasis.…”

Section: Discussionsupporting

confidence: 52%

Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC

Almatroodi

McDonald

Darby

et al. 2015

Cancer Microenvironment

117

104

View full text Add to dashboard Cite

Lung cancer is one of the most commonly reported cancers, and is known to be associated with a poor prognosis. The function of tumour-associated macrophages (TAMs) in lung cancer patients is multifaceted and the literature shows conflicting roles. (I) To analyze the Th1 and Th2 cytokine levels that contribute to the differentiation of M1 and M2 macrophage populations in the serum of patients with NSCLC versus non-cancer controls; and (II) To characterize the M1 and M2 macrophage populations within TAMs in different subtypes of NSCLC compared to non-tumour tissue. The Th1 and Th2 cytokine levels were analyzed in serum using the Bio-Plex assay. In addition, TAMs subsets from nontumour and tumour tissues were analyzed using immunohistochemistry (IHC). The level of IL-1β, IL-4, IL-6 and IL-8 was found to be increased in the serum of patients with large cell carcinoma but not in other NSCLC subtypes compared to non-cancer controls. In addition, the expression of CD68 and M2 marker CD163 was found to be increased (P≤0.0001) in all NSCLC subtypes compared to non-tumour tissues. In contrast, the expression of iNOS (M1 marker) was decreased in the tumour tissue of patients with adenocarcinoma (P≤0.01) and squamous carcinoma (P≤0.05) but not in large cell carcinoma compared to non-tumour tissue. The results of this study indicate that NSCLC might have the ability to alter phenotype within the lung tumour areas in the local environment (TAMs) but not in the bloodstream in the systemic environment (serum) except for large cell carcinoma.

show abstract

Section: Discussionsupporting

confidence: 52%

Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC

Almatroodi

McDonald

Darby

et al. 2015

Cancer Microenvironment

117

104

View full text Add to dashboard Cite

show abstract

“…Gliomas are ranked as the most aggressive brain tumors; they show a high frequency of invasion mediators such as angiogenic factors and chemokines (small-sized proteins, produced and released locally, intended for localized action) [1][2][3]. Simultaneous evaluation of multiple proteins in serum and cerebrospinal fluid allows for the identification of novel circulating biomarker panels helpful in disease diagnosis and treatment [4].…”

Section: Introductionmentioning

confidence: 99%

“…Simultaneous evaluation of multiple proteins in serum and cerebrospinal fluid allows for the identification of novel circulating biomarker panels helpful in disease diagnosis and treatment [4]. Therefore, in the last few years, proteomic approaches have been used to indicate potential cytokines, chemokines, and angiogenic factors for diagnosis and/or progression of primary brain tumors [1,5,6]. Using throughput xMAP technology, Albulescu et al identified serum profiles of cytokines and angiogenic factors (IL-6, IL-1β, IL-2, IL-10, TNF-α, VEGF, FGF-2, and GM-CSF) altered in glioblastoma patients [1].…”

Section: Introductionmentioning

confidence: 99%

Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients

et al. 2017

View full text Add to dashboard Cite

Background The aim of the study was the evaluation of serum and CSF concentrations of CCL2, IL-8, and sICAM-1 in patients with astrocytic tumors as compared to a group of non-tumoral patients. Methods Chemokine concentrations were measured using the ELISA method.Results Regardless of the parameter tested and the patient group (brain tumor or non-tumoral patients), statistical differences (P < 0.05) were found between concentrations obtained in CSF compared to values obtained in serum for all proteins tested. CSF IL-8 concentrations were significantly elevated in CNS tumor patients as compared to non-tumoral individuals (P = 0.000); serum CCL2 and sICAM-1 concentrations were significantly decreased in CNS tumors in comparison with the comparative group (P = 0.002 and P = 0.026, respectively). Among proteins tested in the serum, a higher area under the ROC curve (AUC) revealed CCL2 compared to sICAM-1 in differentiating subjects with CNS brain tumors from nontumoral subjects. AUC for CSF IL-8 was higher than for its index (CSF IL-8/serum IL-8).Conclusions For individual biomarkers (IL-8 and CCL2, sICAM-1), measured in CNS brain tumor patients, the appropriate material, respectively CSF or serum, should be chosen and quantitatively tested. Increased cerebrospinal fluid IL-8 with decreased serum CCL2 create a pattern of biomarkers, which may be helpful in the management of CNS astrocytic brain tumors.

show abstract

“…Glioblastoma is ranked as the most highly aggressive brain tumor which has high expression of mediators of invasion such as angiogenic factors and chemokines (Albulescu et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Expression of Chemokines and Chemokine Receptors in Brain Tumor Tissue Derived Cells

Razmkhah

Arabpour²,

Taghipour³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Chemokine and chemokine receptor expression by tumor cells contributes to tumor growth and angiogenesis and thus these factors may be considered as tumor markers. Here we aimed to characterize cells directly extracted from glioma, meningioma, and secondary brain tumors as well as non-tumoral cells in vitro. Cells were isolated from brain tissues using 0.2% collagenase and characterized by flow cytometry. Expression of SDF-1, CXCR4, CXCR7, RANTES, CCR5, MCP-1 and IP-10 was defined using flow cytometry and qRT-PCR methods. Brain tissue isolated cells were observed as spindle-shaped cell populations. No significant differences were observed for expression of SDF-1, CXCR4, CXCR7, RANTES, CCR5, and IP-10 transcripts. However, the expression of CXCR4 was approximately 13-fold and 110-fold higher than its counterpart, CXCR7, in meningioma and glioma cells, respectively. CXCR7 was not detectable in secondary tumors but CXCR4 was expressed. In non tumoral cells, CXCR7 had 1.3-fold higher mRNA expression than CXCR4. Flow cytometry analyses of RANTES, MCP-1, IP-10, CCR5 and CXCR4 expression showed no significant difference between low and high grade gliomas. Differential expression of CXCR4 and CXCR7 in brain tumors derived cells compared to non-tumoral samples may have crucial impacts on therapeutic interventions targeting the SDF-1/CXCR4/CXCR7 axis.

show abstract

Cytokine Patterns in Brain Tumour Progression

Cited by 137 publications

References 46 publications

Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC

Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC

Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients

Expression of Chemokines and Chemokine Receptors in Brain Tumor Tissue Derived Cells

Contact Info

Product

Resources

About